Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Healthcare

Annexon adds $100m
The round pushed the overall funding for the Novartis-backed autoimmune and neurodegenerative disorder drug developer past $250m.
Bolt latches onto series C financing
Novo, Pfizer and Nan Fung helped provide $93.5m for the cancer treatment developer as it advances its lead product candidate towards the clinic.
CapitalBio Technology cashes $113m
Sinopec Capital and Meinian Onehealth both invested in the biotech research product maker as it prepares for an initial public offering.
Goldfinch Bio holds on to $100m
Existing backer Gilead Sciences returned for a series B round that boosted the kidney disease therapy developer's total funding to $160m.
Genor Biopharma generates filing for $320m IPO
The autoimmune disease and cancer drug developer plans to float in Hong Kong having recently secured $160m from investors including a Charoen Pokphand-backed fund.
Novo gets in Freeline for $120m round
The pharmaceutical company co-led a series C round for AAV gene therapy developer Freeline that took its total funding to $275m.
Berkeley Lights works towards $100m IPO
The cell biology technology provider, which counts Nikon and Varian Medical among its investors, has raised about $215m in venture funding.
Pandion plans $75m initial public offering
SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Other News

Simcha shakes down $25m
Wuxi AppTec and Pfizer contributed to a series A round that will support progress of Simcha Therapeutics' immuno-oncology treatments toward clinical trials.
Akouos acquires $213m in initial public offering
The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.
Fusion Pharma fetches $213m in IPO
Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.
Poseida slots in $110m ahead of IPO
Novartis and Transposagen-backed gene and cell therapy developer Poseida Therapeutics closed the series D round two days after filing to go public.
Enterome enters series E stage
Nestlé Health Science and Takeda participated in a series E round for Enterome, which received $52.6m in equity and debt financing through the deal.
Artiva arrives with $78m
Artiva Biotherapeutics is leveraging GC LabCell’s cell therapy technology to target cancer, and has raised series A funding from backers including the latter.

Editor's Picks

Forma Therapeutics finishes IPO at $319m
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Forma forces its way to $278m IPO
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
Avidity achieves $259m initial public offering
Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.
Oric ordains $120m initial public offering
Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.
test reg

Login